![]() ![]() Atreca is headquartered in Redwood City, California, the US.įor a complete picture of ATRC-101’s drug-specific PTSR and LoA scores, buy the report here. Its pipeline products are intended for the treatment of breast tumor, lung tumor, colon tumor and other solid tumors. Its technology has partnerships with pharmaceutical companies, academic institutions, non-profit foundations and governmental entities. The company develops proprietary immune repertoire capture technology that act as an engine for the discovery and development of antibody based therapeutics, diagnostics, vaccines and research reagents. It develops novel therapies based on the human immune response. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a. ATRC-101 targets ribonucleoprotein (RNP) complex, it binds to a polyadenylate-binding protein (PABP-1) within its target RNP complex.Ītreca is a biotechnology company. SAN CARLOS Calif., (GLOBE NEWSWIRE) - Atreca, Inc. The drug candidate is an engineered, fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally-occurring human antibody developed through driver antigen engagement program based on immune repertoire capture (IRC) technology. It is administered as intravenous infusion. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.ĪTRC-101 is under development for the treatment of solid tumors including non-small cell lung adenocarcinoma, acral melanoma, colorectal cancer, epithelial ovarian cancer, hepatocellular carcinoma, triple negative breast cancer, head and neck cancer squamous cell carcinoma, esophageal squamous cell carcinoma (ESCC), transitional cell carcinoma (urothelial cell carcinoma) and breast adenocarcinoma. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |